Mizuho initiated coverage of AxoGen (AXGN) with an Outperform rating and $40 price target The firm sees a favorable share setup into the upcoming FDA action date of December 5, where it expects a positive outcome. Channel checks indicate a potential 10% uplift in Avance utilization post the application approval, the analyst tells investors in a research note. In addition, Mizuho’s November 2025 breast survey findings forecasts Avance mix in reconstruction surgeries to increase 30% over the next two years.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen price target raised to $26 from $25 at H.C. Wainwright
- AxoGen’s Strong Financial Performance and Strategic Advancements Justify Buy Rating
- AxoGen’s Strong Market Position and Growth Potential Justify Buy Rating
- AxoGen price target raised to $27 from $24 at Canaccord
- AxoGen price target raised to $34 from $26 at Citizens JMP